Background
Vitamin E ( ␣ -tocopherol) is a lipid-soluble vitamin with antioxidant properties which may decrease freeradical-mediated damage in neuronal cells. Many, but not all, observational studies have suggested a protective effect of vitamin E with or without other antioxidant vitamins for the prevention of cognitive decline and Alzheimer's disease (AD) [1] [2] [3] [4] [5] . Because of both laboratoryand population-based data, vitamin E has been proposed as a treatment to delay neurodegeneration in AD patients. One randomized clinical trial in moderately severe AD patients resulted in a significant delay in disease progression (death, institutionalization, loss of activities of daily living, and Clinical Dementia Rating score increase) in patients assigned 2,000 IU/day of vitamin E compared to placebo [6] . However, a trial of 2,000 IU of vitamin E daily had no effect on delaying the progression of AD in participants with amnestic mild cognitive impairment [7] . 537 The AD and Memory Disorders Center (ADMDC) at the Baylor College of Medicine, Houston, Tex., USA, has served as a referral center for AD diagnosis and treatment for over 20 years. Between 1992 and 2004, standard practice in the Baylor ADMDC was to recommend vitamin E supplementation at a dose of 1,000 IU 2 times per day to all AD patients, in addition to any other indicated antidementia drugs. Prior to 1992, some patients self-supplemented themselves, although usually at lower doses than 2,000 IU/day. After 2004, patients continued to receive this recommendation and were given an information sheet summarizing the potential benefits and risks reported in the literature. The purpose of this study was to determine if treatment with vitamin E was associated with higher mortality in the Baylor ADMDC AD cohort.
Patients and Methods

Subjects
Patients were eligible for the study if they had agreed to have their clinical data stored in a database approved by the institutional review board at the Baylor College of Medicine, met the criteria for a diagnosis of probable AD based on the NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association) [11] , and had at least 1 complete comprehensive annual follow-up evaluation after their initial visit. Patients who presented with significant strokes at baseline or met criteria for probable ischemic vascular dementia (NINDS-AIREN, National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherche et l'Enseignement en Neurosciences) were excluded, even if AD was suspected. However, patients who met NINCDS criteria for probable AD but had cerebrovascular changes (extensive white matter disease or lacunae in noncortical regions), or who developed a stroke after the probable AD diagnosis, were included in order to examine the impact of concomitant cardiovascular disease (CVD) on survival. All patients underwent an evaluation by a neurologist and completed a standardized dementia workup that has been in continuous use since 1989 [12] . The analysis included all patients in the cohort who met the eligibility criteria through the censoring date of December 31, 2004.
Measures
The initial visit included a detailed history and interview with the patient and informant, neurological and physical examinations, a neuroimaging study of the brain, neuropsychological testing and screening laboratory studies. The duration of illness was estimated by the physician at the new patient's visit by a standardized procedure reported to the nearest half-year [13] . The initial battery of neuropsychological tests, along with a neurological and physical exam, were repeated annually.
Drugs approved for the treatment of AD first became available in the USA in 1993. The first class of drugs developed for AD consisted of the cholinesterase inhibitors (ChEI) including tacrine (no longer available due to side effects), galantamine, rivastigmine and donepezil. Memantine, a drug that modulates glutamate via N-methyl-D -aspartate receptor antagonism, was approved in 2003 for the treatment of moderate-to-severe AD. Since 1992, the Baylor ADMDC has recommended the use of vitamin E as a supplement to other antidementia treatment or alone if other treatments are contraindicated. At each visit, the patient's medication history during the interval between visits, including his or her vitamin E use, was recorded on a standardized form and stored in the electronic data base.
Baseline neuropsychological testing included the MMSE (Mini-Mental State Examination) [14] , a widely used dementia severity test with scores that range from 0 to 30 points. The description of the full battery of neuropsychological tests used in the ADMDC cohort has been described elsewhere [12] .
The vital status of each actively followed patient was updated every 6 months by telephone follow-up and searches of the National Death Index.
Analysis
Medication exposure during the interval between each patient's visits was represented with indicator variables representing the classes of medications taken by the patient. Thus, for example, any ChEI use since the last visit was coded as 1, and 0 otherwise. For the survival analysis, a single variable, representing mutually exclusive exposure categories in each interval, was created to reflect the following combinations: no drug use (reference category), vitamin E alone or with another antidementia drug, and ChEI without vitamin E. After 2003, some regimens included memantine. Between 2003 and 2004, the number of patients taking memantine alone was too small to be analyzed as a separate group. Approximately 5% of the patients classified as taking vitamin E with or without a ChEI during this period could also have taken memantine.
Time-dependent Cox survival models were constructed to test the effects of the independent medication exposure variables on survival, adjusting for potential confounders including age at diagnosis, sex, race (white or nonwhite), years of education, duration of symptoms, baseline severity of disease based on MMSE score [14] (20-30 = mild; 10-19 = moderate; 0-9 = severe), and presence of relevant cerebrovascular disease features on imaging.
Two survival models were tested, one in which patients on any regimen that included vitamin E were compared to those not taking vitamin E (including patients taking no antidementia drugs), and one in which 3 groups were compared: (1) patients on antidementia drug regimens that included vitamin E; (2) patients on regimens that did not include vitamin E, and (3) a no drug treatment reference group.
Results
The characteristics of the 847 patients who met the basic inclusion criteria are shown in table 1 . The average age at the baseline visit was 73.5 ( 8 8.6) years, and 67.3% of the subjects were female. The severity of the disease at baseline was classified as mild in 52%, moderate in 36% and severe in 12% of the cases. The average survival from first ADMDC visit to death was 5.5 8 2.8 years (median survival: 5.0 years). The earliest cohort entry date for the patients included in the analysis was January 2, 1990, and the latest entry date was January 23, 2003.
Drug exposure information on the interval before any given visit could not be determined with certainty in approximately 10% of the visits. Because of the longitudinal nature of the data, the patients with undetermined drug exposure varied from interval to interval. In table 2 , we report the distribution of exposure to each defined category of antidementia drugs (including vitamin E) for the first ADMDC visit, the second ADMDC visit (required for inclusion in the cohort) and the last ADMDC visit. At the first ADMDC visit, 54% of the patients for whom drug exposure information was available were not taking any antidementia medication, and just over 25% were taking vitamin E alone or with a ChEI. By the final visit, 62% of the patients were taking both vitamin E and a ChEI, 9% were taking vitamin E alone, 13% were taking a ChEI without vitamin E, and 16% were not taking any drug.
In the first Cox survival model ( table 3 ) , in which vitamin E use was compared to no vitamin E use, vitamin E use was associated with a 29% reduction in mortality risk (hazard ratio, HR = 0.71; 95% CI: 0.57-0.89; p = 0.003) after adjusting for age, sex, race and the baseline severity of symptoms. Neither education nor the duration of symptoms before the baseline visit nor concurrent cerebrovascular disease was significantly associated with survival.
In the model in which no drug treatment served as the reference group for vitamin E use (with or without a ChEI) and ChEI use without vitamin E, there was no survival benefit with ChEI use alone (HR = 1.20; 95% CI: 0.87-1.65; p = 0.273), whereas those taking vitamin E with or without a ChEI had a 23% lower mortality risk compared to those not taking any drugs (HR = 0.77; 95% CI: 0.60-1.00; p = 0.051).
The survival functions associated with the 3 categories of drug exposure evaluated in model 2 are depicted in figure 1 . The survival curves indicate that the survival advantage associated with vitamin E use does not become apparent until after 4 or more years of follow-up.
Discussion
There was no evidence that treatment with high doses of vitamin E had an adverse effect on survival in an AD cohort followed up for up to 15 years. In fact, patients whose regimens included vitamin E tended to survive longer than those taking no drug or a ChEI alone. It is noteworthy that the survival benefit to those taking vitamin E did not become apparent until after 4 or more years of follow-up.
The results of this study do little to resolve the controversies over the benefits and risks of vitamin E supplementation in the prevention or treatment of AD. In spite of significant protective effects seen against cancer, heart disease and dementia in some, but not all, observational studies, randomized clinical trials have generally failed Values denote means 8 SD or ranges (column 3), unless specified otherwise. to show a benefit in those taking the supplement. The most recent negative result was announced in November 2008, when a large NIH-sponsored prostate cancer prevention trial, the Selenium and Vitamin E Cancer Prevention Trial (SELECT) [15] (http://www.crab.org/select), was stopped due to evidence of a lack of benefit with regard to the primary endpoint, accompanied by statistically nonsignificant trends toward harm (e.g. higher incidence of type 2 diabetes), among those treated with 400 IU vitamin E and/or 200 g selenium per day. The SELECT included a substudy examining the effects of vitamin E and selenium on the prevention of dementia, but no results from that substudy have been announced yet. The study of vitamin E and selegiline to prevent progression in moderate AD reported by Sano et al. [6] in 1997 remains the only randomized clinical trial that supports both the safety and efficacy of high-dose vitamin E supplementation in AD. The dose of vitamin E tested in this trial was 2,000 IU per day. Of the trials included in the meta-analysis by Miller et al. [9] , only one other, in a Parkinson's disease population, tested a dose as high as 2,000 IU per day. The trend toward a dose-related increase in mortality with higher doses of vitamin E led Miller et al. [9] to advise against a supplementation with more than 400 IU per day.
Roberts et al. [16] argued that little was known about dose-dependent effects of vitamin E on the suppression of oxidative stress and conducted a dosing and time course study on individuals with elevated plasma cholesterol. They found that the peak reduction of oxidative stress, as measured by plasma F 2 -isoprostane, did not occur until week 16 of the supplementation with 3,200 IU per day, and that a significant reduction in F 2 -isoprostane levels did not occur with doses less than 1,600 IU per day. These authors concluded that the results of both observational and experimental studies on vitamin E effects were difficult to interpret because of the lack of documenta- The duration of symptoms, education and CVD was nonsignificant (p > 0.20) in all models (HR not shown). tion of the relationship between vitamin E dosage and change in oxidative stress. Patients in most clinical treatment trials are followed up for less than 5 years. The fact that the survival curves in our AD cohort did not begin to diverge until after 4 years of follow-up raises the possibility that the benefits of vitamin E supplementation are difficult to observe under the constraints of a randomized trial. Another factor that must be considered in evaluating the results is that only 6% of the patients in our AD cohort had features of concurrent cerebrovascular disease, and the population is thus quite different from that included in trials that have evaluated vitamin E supplementation to prevent cardiovascular and cerebrovascular outcomes. We adjusted for the presence of CVD in our analysis, but the number of patients with this feature was too small to be analyzed separately.
The results of our observational study in an AD cohort are not consistent with a harmful effect of vitamin E on overall survival. In light of the potential for beneficial effects and mixed clinical trial evidence, they emphasize the need for additional research on vitamin E supplementation in AD using a dose range that extends above 400 IU per day.
The strength of our study is that it includes a large number of AD patients followed up over a relatively long period of time with a standardized documentation of medication history and outcomes. In addition, the study reflects the outcomes of actual clinical practice in AD treatment.
The findings of the study must be interpreted with caution in view of its observational nature. The numbers of patients grouped in the different medication exposure categories were not equal, and selection factors associated with long-term drug exposure cannot be ruled out as alternative explanations for the findings.
